A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
The purpose of this study is to determine the safety and efficacy of an investigational study drug DN-101 (calcitriol) when given in combination with gemcitabine ± erlotinib in the treatment of pancreatic cancer.
Pancreatic Cancer
DRUG: placebo + gemcitabine + erlotinib|DRUG: Placebo + gemcitabine|DRUG: calcitriol + gemcitabine|DRUG: calcitriol + gemcitabine + erlotinib
Overall survival rate at 6 months
Objective response rate|Duration of progression free survival|Duration of overall survival
The purpose of this study is to determine the safety and efficacy of an investigational study drug DN-101 (calcitriol) when given in combination with gemcitabine ± erlotinib in the treatment of pancreatic cancer.